Skip to main content
. 2017 Oct 27;8(61):104206–104215. doi: 10.18632/oncotarget.22171

Figure 1. Role of miR-216b in chemosensitivity of NSCLC cells to cisplatin treatment.

Figure 1

(A) QRT-PCR analysis was performed to evaluate the change of miR-216b expression when the A549 and PC9 NSCLC cells were under the cisplatin treatment. *P<0.05. (B) Effect of miR-216b mimics (50 pmol/ml) or inhibitors (50 pmol/ml) on changing cellular level of miR-216b in A549 and PC9 NSCLC cells. *P<0.05 vs. NCO group. #P<0.05 vs. cisplatin + NCO group. (C) MTT assay was performed to evaluate the effect of miR-216b mimics (50 pmol/ml) or inhibitors (50 pmol/ml) on changing IC50 of cisplatin to A549 cells. *P<0.05 vs. NCO group. (D) Effect of miR-216b mimics (50 pmol/ml) or inhibitors (50 pmol/ml) on changing IC50 of cisplatin to PC9 cells. *P<0.05 vs. NCO group.